Share ownership Merck & Co., Inc.

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:18 11/04/2026 HKT			5-day change	1st Jan Change
121.42 ^USD	-1.03%		+0.46%	+15.35%

04-09	Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says	MT
04-09	Merck CEO Pay Falls 10% in 2025 Due to Lower Stock, Option Awards	DJ

Share class: Merck & Co., Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	3,577,103,522	2,528,032,964 ( 70.67 %)	1,045,073,377 ( 29.22 %)	70.67 %

Major shareholders: Merck & Co., Inc.

Name	Equities	%	Valuation
Vanguard Fiduciary Trust Co. 10.29 %	254,322,763	10.29 %	31 490 M $
BlackRock Advisors LLC 6.509 %	160,933,559	6.509 %	19 927 M $
STATE STREET CORPORATION 4.855 %	120,040,168	4.855 %	14 863 M $
Wellington Trust Co., NA 3.496 %	86,435,458	3.496 %	10 702 M $
Geode Capital Management LLC 2.429 %	60,047,984	2.429 %	7 435 M $
BlackRock Life Ltd. 2.08 %	51,436,428	2.08 %	6 369 M $
Charles Schwab Investment Management, Inc. 1.964 %	48,563,804	1.964 %	6 013 M $
Eaton Vance Management 1.818 %	44,946,021	1.818 %	5 565 M $
Fidelity Management & Research Co. LLC 1.649 %	40,767,953	1.649 %	5 048 M $
Norges Bank (13F) 1.536 %	37,981,502	1.536 %	4 703 M $
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Caixa DTVM SA 0.001077 %	213,040	0.001077 %	3 M $
Safra Asset CTVM SA (Investment Management) 0.000247 %	48,900	0.000247 %	743 939 $
XP Allocation Asset Management Ltda. 0.000027 %	5,257	0.000027 %	79 977 $

Breakdown by shareholder type

Institutional	63.87%
Other	8.53%
State Street Corp.	4.86%
Swedbank AB	0.31%
Sumitomo Mitsui Trust Group, Inc.	0.28%
Schweizerische Nationalbank	0.28%
Governments	0.15%
SEI Investments Co.	0.11%
The Bank of Nova Scotia	0.08%
Danske Bank A/S	0.08%
Manulife Financial Corp.	0.07%
Skandinaviska Enskilda Banken AB	0.07%
Individuals	0.05%
Regions Financial Corp.	0.05%
Münchener Rückversicherungs-Gesellschaft AG	0.04%
ING Groep NV	0.03%
First Financial Bankshares, Inc.	0.03%
Old Republic International Corp.	0.03%
Fifth Third Bancorp	0.02%
Peapack-Gladstone Financial Corp.	0.02%
Zurich Insurance Group AG	0.02%
Banco Bilbao Vizcaya Argentaria SA	0.02%
Ally Financial, Inc.	0.01%
Fairfax Financial Holdings Ltd.	0.01%
The Allstate Corp.	0.01%
ABN AMRO Bank NV	0.01%
Cullen/Frost Bankers, Inc.	0.01%
Silvercrest Asset Management Group, Inc.	0.01%
Rathbones Group Plc	0.01%
Hancock Whitney Corp.	0.01%
Commerzbank AG	0.01%
Unknown	20.91%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	59.5%
United Kingdom	7.86%
Canada	2.28%
Norway	1.74%
Sweden	1.03%
France	0.97%
Australia	0.79%
Japan	0.79%
Switzerland	0.75%
Denmark	0.68%
Germany	0.48%
Netherlands	0.34%
Hong Kong	0.33%
South Korea	0.32%
Ireland	0.19%
Italy	0.18%
Luxembourg	0.16%
Malaysia	0.1%
Belgium	0.1%
Spain	0.09%
Finland	0.09%
New Zealand	0.07%
Individuals	0.05%
Austria	0.05%
Singapore	0.05%
Czech Republic	0.03%
Liechtenstein	0.02%
Saudi Arabia	0.01%
Brazil	0.01%
Puerto Rico	0.01%
South Africa	0.01%
Slovenia	0.01%
China	0.01%

Based on 1000 largest holdings

Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (73.9%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (15.5%); - sale of animal health products (9.8%); - other (0.8%). Net sales are distributed geographically as follows: the United States (56.2%), Europe/Middle East/Africa (22.4%), Latin America (5.2%), Asia/Pacific (4.6%), Japan (4.2%), China (3%) and other (4.4%).

Employees

74,000

Sector

Pharmaceuticals

More about the company